Treatment-induced menstrual changes in very young (<35 years old) breast cancer patients
- 103 Downloads
To evaluate the treatment-induced menstrual changes in very young (< 35 years old) breast cancer patients.
Methods and materials
We retrospectively examined the clinical records of 160 patients, ranging in age from 18 to 34 years old (median age, 32 years), treated between June 1992 and December 2002. One hundred twenty patients underwent mastectomy and 40 underwent breast conserving surgery. Postoperatively, 80 patients were treated with alkylating agent-based chemotherapy regimens (CMF) and 80 with anthracycline-based regimens (AD). In addition, 57 patients received adjuvant radiotherapy, and 77 received anti-estrogen therapy. Treatment-induced menstrual changes and present menstrual status were evaluated from hospital records and by one-to-one interviews. The median follow-up period was 54 months (range, 29–156 months).
Treatment-induced menstrual change (amenorrhea) was occurred in 59 (36.9%) patients, 25 (31.3%) of those treated with CMF and 34 (42.5%) with AD (p=0.142). Amenorrhea occurred after a median 2 cycles of chemotherapy (range, 1–6 cycles). Menstruation resumed in 49 (83.1%) patients, 20 (80%) of those treated with CMF and 29 (85.3%) with AD (p=0.6). Median time to resumption of menstruation was median 3.5 months (range, 1–18 months) after amenorhrea. Disease recurred in 10 (16.9%) patients who experienced treatment-induced menstrual changes and in 18 (17.8%) of those who did not (p=0.89).
Although the overall incidence of treatment-induced menstrual change in breast cancer patients under age 35 was similar to that reported elsewhere, the rate of recovery from these change is higher. We observed no difference between CMF and AD treated patients in rates of amenorrhea or recovery from these changes.
Keywordsbreast cancer treatment-induced menstrual changes very young (<35 years old) age
Unable to display preview. Download preview PDF.
- 8.NIH Consensus Development Program: Adjuvant Therapy for Breast Cancer. National Institutes of Health Consensus Development Statement, November 1–3, 2000Google Scholar
- 19.Nabholtz J, Pienkowski T, Mackey J, et al Phase III trial comparing TAC with FAC in the adjuvant treatment of node positive breast cancer patients: Interim analysis of the BCIRG 001 study Proc Am Soc Clin Oncol 21(abstr 141):361, 2002Google Scholar
- 20.Hortobagyi GN, Buzdar AU, Marcus CE, Smith TL, Immediate and long-term toxicity of adjuvant chemotherapy regimens containing doxorubicin in trials at M.D. Anderson Hospital and Tumor Institute NCI Monogr 1:105–109, 1986Google Scholar
- 21.Levine MN, Bramwell VH, Pritchard KI, et al Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluoruracil in premenopausal women with node-positive breast cancer: National Cancer Institute of Canada Clinical Trials Group J Clin Oncol 16:2651–2658, 1998CrossRefPubMedGoogle Scholar